the product in the database has an inactive status
indications:
Prominently in combination with β-blockers. In monotherapy, when beta blockers therapy is ineffective or contraindicated, in the treatment of increased intraocular pressure in patients with ocular hypertension, open-angle glaucoma or capillary glaucoma.
Composition:
1 ml of solution contains 20 mg of dorzolamide in the form of hydrochloride.
Action:
A strong carbonic anhydrase II inhibitor for topical administration. Inhibition of carbonic anhydrase in the ciliary processes of the eye reduces the amount of aqueous humor released. As a result, the intraocular pressure is reduced. After topical administration, dorzolamide lowers the increased intraocular pressure, whether it is associated with glaucoma or not. After topical application, dorzolamide passes into the systemic circulation. Dorzolamide is excreted mainly in the urine in unchanged form.
Contraindications:
Hypersensitivity to the components of the preparation. Severe renal failure (creatinine clearance <30 ml / min). Hyperlloric acidosis.
Precautions:
The use of the preparation has not been studied in patients with hepatic insufficiency (caution should be exercised) and in patients with acute angle-closure glaucoma. The preparation should be discontinued if hypersensitivity reactions or serious side effects occur (side effects typical of sulphonamides generally administered). Due to the risk of urolithiasis caused by water and electrolyte disturbances, the drug should be used with caution in patients with a history of urinary calculi. Co-administration of dorzolamide and oral carbonic anhydrase inhibitors is not recommended. Carefully use in patients with pre-existing chronic corneal defects and / or intraocular surgery (risk of corneal edema and irreversible corneal decompensation). The preparation has not been tested in children before 36 weeks of fetal life and less than 1 week of age. In patients with significant immaturity of the renal tubules, dorzolamide should only be used after careful consideration of the benefit to risk, due to the possibility of metabolic acidosis.
Pregnancy and lactation:
No tests, do not use during pregnancy unless absolutely necessary. Do not use during breast-feeding.
Side effects:
Very often: burning and stinging in the eye. Common: headache, superficial punctate keratitis, tearing, conjunctivitis, blepharitis, itchy eyes, eyelid irritation, blurred vision, nausea, bitter aftertaste, asthenia / fatigue. Uncommon: inflammation of the iris and ciliary body. Rarely: dizziness, redness of the eye, eye pain, sticky eyelids, transient myopia (receding after cessation of therapy), corneal edema, reduced intraocular pressure, choroidal detachment after filtration, paresthesia, dizziness, nosebleeds, throat irritation, dryness mouth, contact dermatitis, urolithiasis, hypersensitivity reactions (local reactions and symptoms of general allergic reactions: angioneurotic edema, bronchospasm, dyspnoea, urticaria, pruritus, rash). In children, the following were observed: burning and stinging in the eye, conjunctival hyperaemia, eye pain; less frequently (<4%) swelling and occlusion of the cornea, sporadic - metabolic acidosis (in very young patients, particularly immaturity or impaired renal function).
Dosage:
Monotherapy: 1 drop into the conjunctival sac of the affected eye (eyes) 3 times a day. In adjunctive therapy in combination with the topically applied beta-blocker: 1 drop into the conjunctival sac of the affected eye (eyes) twice a day. In patients treated with another antiglaucoma drug, dorzolamide is introduced the Next day after discontinuing previous treatment. When using several topical ophthalmic medications, a minimum of 10 minutes should be allowed between the instillation of subsequent medications. Children: Limited data are available on the use of dorzolamide 3 times a day.
(C)
